Marc Tessier-Lavigne - Nov 23, 2022 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Nov 23, 2022
Transactions value $
-$609,600
Form type
4
Date filed
11/28/2022, 06:30 PM
Previous filing
Nov 3, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$610K -20K -1.06% $30.48 1.87M Nov 23, 2022 Direct F1, F2, F3
holding DNLI Common Stock 78.8K Nov 23, 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 1 F4
holding DNLI Common Stock 79.2K Nov 23, 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 2 F5
holding DNLI Common Stock 78.8K Nov 23, 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 3 F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.15 to $31.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 5,986 unvested restricted stock units.
F4 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
F5 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
F6 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.